| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 University of Utah and Veteran Affairs Medical Center, Division of Nephrology and Hypertension, 30 N 1900 E, Rm 4R312, Salt Lake City, Utah, 84132, United States
2 Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
3 Medical College of Georgia, Augusta, Georgia, United States
* To whom correspondence should be addressed. E-mail: zdong{at}mail.mcg.edu.
Cisplatin, a widely used chemotherapy drug, induces acute kidney injury, which limits its use and efficacy in cancer treatment. However, the molecular mechanism of cisplatin-induced nephrotoxicity is currently unclear. Using pharmacological and gene knockout models, we now demonstrate a pathological role for p53 in cisplatin nephrotoxicity. In C57BL/6 mice, cisplatin treatment induced p53 phosphorylation and protein accumulation, which was accompanied by the development of acute kidney injury. p53 was induced in both proximal and distal tubular cells and partially co-localized with apoptosis. Pifithrin-
, a pharmacological inhibitor of p53, suppressed p53 activation and ameliorated kidney injury during cisplatin treatment. Moreover, cisplatin-induced nephrotoxicity was abrogated in p53-deficient mice. Compared with wild-type animals, p53-deficient mice showed a better renal function, less tissue damage, and fewer apoptotic cells. In addition, cisplatin induced less apoptosis in proximal tubular cells isolated from p53-deficient mice than the cells from wild-type animals. Together these results suggest the involvement of p53 in cisplatin-induced renal cell apoptosis and nephrotoxicity.
This article has been cited by other articles:
|
|
 |
|
  K. P. Kang, D. H. Kim, Y. J. Jung, A. S. Lee, S. Lee, S. Y. Lee, K. Y. Jang, M. J. Sung, S. K. Park, and W. Kim Alpha-lipoic acid attenuates cisplatin-induced acute kidney injury in mice by suppressing renal inflammation Nephrol. Dial. Transplant., October 1, 2009; 24(10): 3012 - 3020. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. A. Molitoris, P. C. Dagher, R. M. Sandoval, S. B. Campos, H. Ashush, E. Fridman, A. Brafman, A. Faerman, S. J. Atkinson, J. D. Thompson, et al. siRNA Targeted to p53 Attenuates Ischemic and Cisplatin-Induced Acute Kidney Injury J. Am. Soc. Nephrol., August 1, 2009; 20(8): 1754 - 1764. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Jiang, C.-Y. Wang, S. Huang, T. Yang, and Z. Dong Cisplatin-induced apoptosis in p53-deficient renal cells via the intrinsic mitochondrial pathway Am J Physiol Renal Physiol, May 1, 2009; 296(5): F983 - F993. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Singaravelu, K. Devalaraja-Narashimha, B. Lastovica, and B. J. Padanilam PERP, a p53 proapoptotic target, mediates apoptotic cell death in renal ischemia Am J Physiol Renal Physiol, April 1, 2009; 296(4): F847 - F858. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Pabla, R. F. Murphy, K. Liu, and Z. Dong The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity Am J Physiol Renal Physiol, March 1, 2009; 296(3): F505 - F511. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Sutton, J. Wilkinson, H. E. Mang, N. L. Knipe, Z. Plotkin, M. Hosein, K. Zak, J. Wittenborn, and P. C. Dagher p53 regulates renal expression of HIF-1{alpha} and pVHL under physiological conditions and after ischemia-reperfusion injury Am J Physiol Renal Physiol, December 1, 2008; 295(6): F1666 - F1677. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Jiang and Z. Dong Regulation and Pathological Role of p53 in Cisplatin Nephrotoxicity J. Pharmacol. Exp. Ther., November 1, 2008; 327(2): 300 - 307. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |
